|Articles|April 1, 2004

CAT-192 APPEARS TOLERABLE

Cambridge Antibody Technology and Genzyme Corp. announced preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGF(Beta)1 monoclonal antibody. The primary objective of the trial was to assess the safety, tolerability, and pharmacokinetics of CAT-192 in patients suffering from diffuse systemic sclerosis.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME